Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 511-520

  Shalinsky, David R ^a   Bischoff, Eric D ^a   Gregory, Margaret L ^a   Lamph, William W ^a   Heyman, Richard A ^a   Hayes, J Scott ^a   Thomazy, Vilmos ^b   Davies, Peter J A ^b  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CISPLATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MOUTH CARCINOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BROMODEOXYURIDINE; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HUMANS; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TRETINOIN;

EID: 0029970608     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Einhorn, L. H., and Williams, S. D. The role of cis-platinum in solid-tumor therapy. N. Engl. J. Med., 300: 289-291, 1979.
2. Loehrer, P. J., and Einhorn, L. H. Cisplatin. Diagnosis and treatment: drugs five years later. Ann. Intern. Med., 100: 704-713, 1984.
3. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990.
4. Lippman, S. M., Kessler, F. L., and Meyskens, F. L., Jr. Retinoids as preventive and therapeutic anticancer agents (part II). Cancer Treat. Rep., 71: 493-515, 1987
5. Huber, M. H., Lippman, S. M , and Hong, W. K. Chemoprevention of head and neck cancer. Semin. Oncol., 21: 366-375, 1994.
6. Bollag, W., and Hartmann, R. Prevention and therapy of cancer with retinoids in animals and man. Cancer Surv., 2: 293-314, 1983.
7. Meyskens, F. L., Jr., Gilmartin, E., Alberts, D. S., Levine, N. S., Brooks, R., Salmon, S. E., and Surwit, E. A. Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat. Rep., 66: 1315-1319, 1982.
8. Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E. N., and Vaughan, C. 13-Cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med., 315: 1501-1505, 1986.
9. Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., Dimery, I. W., Brown, B. W., and Goepfert, H. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795-801, 1990.
10. DeLuca, L. M. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J., 5: 2924-2933, 1993,
11. Amos, B., and Lotan, R. Retinoid-sensitive cells and -cell lines. Methods Enzymol., 190: 217-225, 1990.
12. Lotan, R. Squamous differentiation and rerinoids. In: W. K. Hong and R. S. Weber, eds.), Cancer Treatment and Research Series: Head and Neck Oncology IV, pp. 43-72. Norwell. MA: Kluwer Academic Publishing, 1994.
13. Sacks, P. J., Harris, D., and Chou, T-C. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination chemotherapy with chemotherapeutic agents. Int. J. Cancer, 61: 1-7, 1995.
14. Aebi, S., Kroning, R., Jones, J. A., Naredi, P., Los, G., Howell, S. B., and Christen, R. D. All-trans retinoic acid (ATRA) enhances the activity of cisplatin (DDP) m head and neck cancer and ovarian cancer cell lines. Proc. Am. Assoc. Cancer Res., 36: 287, 1995.
15. Caliaro, M. J., Lochon, I., Nehme, A., Lafon, C., Vaette, A., Canal, P., Bugat, R., and Jozan, S. Enhancement of cisplatin (CDDP) cytotoxicity by all trans retinoic acid (ATRA) on human ovarian carcinoma cell lines. Proc. Am. Assoc. Cancer Res., 36: 293, 1995.
16. Kalemkerian, G., Slusher, R , Ramalingam, S., and Mabry, M. Fenretinamide inhibits growth and potentiates etoposide cytotoxicity in small cell lung cancer. Proc. Am. Assoc. Cancer Res., 36: 510, 1995.
17. Formelli, F., and Cleris, L. Synthetic retinoid fenretinamide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res., 53: 5374-5376, 1993.
18. Shalinsky, D. R., Bischoff, E. D. Gregory, M. L., Gottardis, M. M., Hayes, J. S., Shirley, M. A . Lamph, W. W., Heyman, R. A., Davies, P. J. A., and Thomazy, V. Retinoid-induced suppression of squamous differentiation of human oral squamous carcinoma cell xenografts (line 1483) in athymic nude mice. Cancer Res., 55: 3183-3191, 1995.
19. Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., and Thaller, C. 9-cis recinoic acid is a high affinity ligand for the retinoid X receptor. Cell, 68: 397-406, 1992.
20. Sharkey, F. E., and Fogh, J. Considerations in the use of nude mice for cancer research. Cancer Metastasis Rev., 3, 341-360, 1984.
21. Lindberg, K., and Rheinwald, J. G. Three distinct keratinocyte subtypes identified in human oral epithelium by their patterns of keratin expression in culture and in xenografts. Differentiation, 45: 230-241, 1990.
22. Heyden, A., Huitfeldt, H. S., Kopang, H. S., Thrane, P. S., and Brandtzaeg, B. M Cytokeratins as epithelial differentiation markers in premalignant and malignant oral lesions. J. Oral Pathol. Med., 21: 7-11, 1992.
23. Sacks, P. G., Parnes, S. M., Gallick, G. E., Mansouri, Z., Lichtner, R., Satya-Prakesh, K. L., Pathak, S., and Parsons, D. F. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res., 48: 2858-2866, 1988.
24. Andrews, P. A., Jones, J. A., Varki, N. M., and Howell, S. B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun., 2: 93-100, 1990.
25. Zou, C-P., Clifford, J. L., Xu, X-C., Sacks, P. G., Chambon, P., Hong, W. K., and Lotan, R. Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. Cancer Res., 54: 5479-5487, 1994.
26. Gottardis, M. M., Lamph, W. W., Shalinsky, D. R., Messick, C. P., Sessions, R. B., Smith, R. V., Wright, A., and Wellstein, A. Antitumor efficacy of retinoids in human primary head and neck squamous cell carcinoma xenografts. Proc. Am. Assoc. Cancer Res. 36: 514, 1995.
27. Thatcher, N., Blackledge, G., and Crowther, D. Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with Adriamycin, bleomycm, 5-fluorouracil, methotrexate, and vitamin A. Cancer (Phila.). 46: 1324-1328, 1980.
28. Sacks, P. G., Oke, V., Calkins, D. P., Vasey, T., and Terry, N. H. A. Effects of β-all-trans-retinoic acid on growth, proliferation, and cell death in a multiceliular tumor spheroid model for squamous carcinomas. J. Cell Physiol., 144: 237-243, 1990.
29. Devita, V. T., Jr. Principles of chemotherapy. In: V. T. Devita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, 2nd ed. pp. 257-285. Philadelphia: J. B. Lippincott Co., 1982.